{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:48:30Z","timestamp":1745300910174},"reference-count":56,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,6]]},"DOI":"10.7759\/cureus.43043","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T03:59:31Z","timestamp":1691380771000},"source":"Crossref","is-referenced-by-count":2,"title":["Hospital, Catheter, Peritoneal Dialysis Acquired Infections: Visible Light as a New Solution to Reduce Risk and Incidence"],"prefix":"10.7759","author":[{"given":"Joseph N","family":"Macaluso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Hospital Acquired Infections","author":"Monegro AF","year":"2021","unstructured":"Monegro AF, Muppidi V, Regunath H. Hospital Acquired Infections. StatPearls Publishing, Treasure Island, FL; 2021."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00027-10","article-title":"Hospital epidemiology and infection control in acute-care settings","volume":"24","author":"Sydnor ER","year":"2011","unstructured":"Sydnor ER, Perl TM. Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev. 2011, 24:141-73. 10.1128\/CMR.00027-10","journal-title":"Clin Microbiol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa373","article-title":"Antimicrobial use in US hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011","volume":"72","author":"Magill SS","year":"2021","unstructured":"Magill SS, O'Leary E, Ray SM, et al.. Antimicrobial use in US hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011. Clin Infect Dis. 2021, 72:1784-92. 10.1093\/cid\/ciaa373","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnc.2018.05.007","article-title":"Hospital costs associated with sepsis compared with other medical conditions","volume":"30","author":"Danna DM","year":"2018","unstructured":"Danna DM. Hospital costs associated with sepsis compared with other medical conditions. Crit Care Nurs Clin North Am. 2018, 30:389-98. 10.1016\/j.cnc.2018.05.007","journal-title":"Crit Care Nurs Clin North Am"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01709-16","article-title":"Increased costs associated with bloodstream infections caused by multidrug-resistant Gram-negative bacteria are due primarily to patients with hospital-acquired infections","volume":"61","author":"Thaden JT","year":"2017","unstructured":"Thaden JT, Li Y, Ruffin F, et al.. Increased costs associated with bloodstream infections caused by multidrug-resistant Gram-negative bacteria are due primarily to patients with hospital-acquired infections. Antimicrob Agents Chemother. 2017, 61:e01709-16. 10.1128\/AAC.01709-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-16","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the International Network for optimal resistance monitoring program in the United States","volume":"61","author":"Sader HS","year":"2017","unstructured":"Sader HS, Huband MD, Castanheira M, Flamm RK. Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the International Network for optimal resistance monitoring program in the United States. Antimicrob Agents Chemother. 2017, 61:e02252-16. 10.1128\/AAC.02252-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2018.18","article-title":"Financial incentives to reduce hospital-acquired infections under alternative payment arrangements","volume":"39","author":"Cohen CC","year":"2018","unstructured":"Cohen CC, Liu J, Cohen B, Larson EL, Glied S. Financial incentives to reduce hospital-acquired infections under alternative payment arrangements. Infect Control Hosp Epidemiol. 2018, 39:509-15. 10.1017\/ice.2018.18","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref8","unstructured":"The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits. (2009). Accessed. March 1, 2009: https:\/\/www.cdc.gov\/hai\/pdfs\/hai\/scott_costpaper.pdf."},{"key":"ref9","article-title":"HCUP Facts and Figures, 2006: Statistics on Hospital-Based Care in the United States","author":"Healthcare Cost and Utilization Project (HCUP)","year":"2008","unstructured":"Healthcare Cost and Utilization Project (HCUP). HCUP Facts and Figures, 2006: Statistics on Hospital-Based Care in the United States. Agency for Healthcare Research and Quality , Rockville, MD; 2008."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.2011.41","article-title":"Increases in mortality, length of stay, and cost associated with hospital-acquired infections in trauma patients","volume":"146","author":"Glance LG","year":"2011","unstructured":"Glance LG, Stone PW, Mukamel DB, Dick AW. Increases in mortality, length of stay, and cost associated with hospital-acquired infections in trauma patients. Arch Surg. 2011, 146:794-801. 10.1001\/archsurg.2011.41","journal-title":"Arch Surg"},{"key":"ref11","unstructured":"HAI Data and Statistics. (2018). Accessed. January 9, 2018: https:\/\/www.cdc.gov\/hai\/data\/index.html."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2019.0467","article-title":"The global prevalence of class 1 integron and associated antibiotic resistance in Escherichia coli from patients with urinary tract infections, a systematic review and meta-analysis","volume":"26","author":"Halaji M","year":"2020","unstructured":"Halaji M, Feizi A, Mirzaei A, Ebrahim-Saraie HS, Fayyazi A, Ashraf A, Havaei SA. The global prevalence of class 1 integron and associated antibiotic resistance in Escherichia coli from patients with urinary tract infections, a systematic review and meta-analysis. Microb Drug Resist. 2020, 26:1208-18. 10.1089\/mdr.2019.0467","journal-title":"Microb Drug Resist"},{"key":"ref13","unstructured":"Making health care safer stop infections from lethal CRE germs now. (2013). Accessed. March 11, 2013: https:\/\/www.cdc.gov\/vitalsigns\/hai\/cre\/."},{"key":"ref14","unstructured":"Types of Healthcare-associated Infections. (2014). Accessed. March 26, 2014: https:\/\/www.cdc.gov\/hai\/infectiontypes.html."},{"key":"ref15","article-title":"Antibiotic resistance threats in the United States","author":"CDC","year":"2019","unstructured":"CDC. Antibiotic resistance threats in the United States. U.S. Department of Health and Human Services, Atlanta, GA; 2019."},{"key":"ref16","unstructured":"Hospital-Acquired Condition Reduction Program (HACRP), Centers for Medicare and Medicaid Services. (2020). Accessed. June 16, 2020: https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/acuteinpatientpps\/hac-reduction-program#:~:text=The%20H...."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2018.01.015","article-title":"The attributable cost of catheter-associated urinary tract infections in the United States: a systematic review","author":"Hollenbeak CS","year":"2018","unstructured":"Hollenbeak CS, Schilling AL. The attributable cost of catheter-associated urinary tract infections in the United States: a systematic review. Elsvier, Inc., New York City, NY; 2018. 10.1016\/j.ajic.2018.01.015"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5492\/wjccm.v6.i1.79","article-title":"Attributable cost of a nosocomial infection in the intensive care unit: a prospective cohort study","volume":"6","author":"Chacko B","year":"2017","unstructured":"Chacko B, Thomas K, David T, Paul H, Jeyaseelan L, Peter JV. Attributable cost of a nosocomial infection in the intensive care unit: a prospective cohort study. World J Crit Care Med. 2017, 6:79-84. 10.5492\/wjccm.v6.i1.79","journal-title":"World J Crit Care Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2174\/1389201020666190408095811","article-title":"Healthcare-associated infections due to multidrug-resistant organisms: a surveillance study on extra hospital stay and direct costs","volume":"20","author":"Giraldi G","year":"2019","unstructured":"Giraldi G, Montesano M, Napoli C, et al.. Healthcare-associated infections due to multidrug-resistant organisms: a surveillance study on extra hospital stay and direct costs. Curr Pharm Biotechnol. 2019, 20:643-52. 10.2174\/1389201020666190408095811","journal-title":"Curr Pharm Biotechnol"},{"key":"ref20","unstructured":"Catheter-associated Urinary Tract Infections (CAUTI). (2017). Accessed. July 19, 2017: https:\/\/www.cdc.gov\/hai\/ca_uti\/uti.html."},{"key":"ref21","unstructured":"Bladder Infection (Urinary Tract Infection) in Adults. (2017). Accessed. March 1, 2017: https:\/\/www.niddk.nih.gov\/health- information\/urologic-diseases\/bladder-infection-uti-in-adults."},{"key":"ref22","unstructured":"CDC global health strategy. (2019). Accessed. April 8, 2021: https:\/\/www.cdc.gov\/globalhealth\/strategy\/default.htm."},{"key":"ref23","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 Continents confirmed by Whole-Genome Sequencing and epidemiological analyses","volume":"15","author":"Lockhart SR","year":"2017","unstructured":"Lockhart SR, Etienne KA, Vallabhaneni S, et al.. Simultaneous emergence of multidrug-resistant Candida auris on 3 Continents confirmed by Whole-Genome Sequencing and epidemiological analyses. Clin Infect Dis. 2017, 15:134-40.","journal-title":"Clin Infect Dis"},{"key":"ref24","unstructured":"Making health care safer stop infections from lethal CRE germs now. Vital signs from Centers for Disease Control. (2021). Accessed. June 18, 2021: https:\/\/www.cdc.gov\/vitalsigns\/hai\/cre\/index.html."},{"key":"ref25","unstructured":"USRDS annual data report. epidemiology of kidney disease in the United States. (2022). Accessed: June 19, 2021: https:\/\/usrds-adr.niddk.nih.gov\/2022\/end-stage-renal-disease\/9-healthcare-expenditures-for-persons-with-esrd."},{"key":"ref26","unstructured":"Hemodialysis. (2023). Accessed. January 1, 2023: https:\/\/www.niddk.nih.gov\/health-information\/kidney-disease\/kidney-failure\/hemodialysis."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2011.09.001","article-title":"Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues","volume":"18","author":"Sinnakirouchenan R","year":"2011","unstructured":"Sinnakirouchenan R, Holley JL. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. Adv Chronic Kidney Dis. 2011, 18:428-32. 10.1053\/j.ackd.2011.09.001","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref28","article-title":"Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues","volume":"18","author":"Sinnakirouchenan R","year":"2011","unstructured":"Sinnakirouchenan R, Holley JL. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. AKDH. 2011, 18:P428-32.","journal-title":"AKDH"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2020.06.209","article-title":"Impact of SARS-CoV-2 on hospital acquired infection rates in the United States: predictions and early results","volume":"48","author":"McMullen KM","year":"2020","unstructured":"McMullen KM, Smith BA, Rebmann T. Impact of SARS-CoV-2 on hospital acquired infection rates in the United States: predictions and early results. Am J Infect Control. 2020, 48:1409-11. 10.1016\/j.ajic.2020.06.209","journal-title":"Am J Infect Control"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0000000000000754","article-title":"What is new in catheter use and catheter infection prevention in the ICU","volume":"26","author":"Buetti N","year":"2020","unstructured":"Buetti N, Tabah A, Timsit JF, Zingg W. What is new in catheter use and catheter infection prevention in the ICU. Curr Opin Crit Care. 2020, 26:459-65. 10.1097\/MCC.0000000000000754","journal-title":"Curr Opin Crit Care"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2016.00106","article-title":"Effect of UV light on disinfection of peritoneal dialysis catheter connections","volume":"37","author":"Ashley J","year":"2017","unstructured":"Ashley J, Rasooly JA, Tran I, Yost LE, Chertow GM. Effect of UV light on disinfection of peritoneal dialysis catheter connections. Perit Dial Int. 2017, 37:109-11. 10.3747\/pdi.2016.00106","journal-title":"Perit Dial Int"},{"key":"ref32","unstructured":"UV Properties of Plastics. Transmission and Resistance. (2021). Accessed: March 5, 2023: https:\/\/www.coleparmer.com\/tech-article\/uv-properties-of-plastics."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22457","article-title":"Violet 405\u2009nm light: a novel therapeutic agent against \u03b2-lactam-resistant Escherichia coli","volume":"48","author":"Rhodes NL","year":"2016","unstructured":"Rhodes NL, de la Presa M, Barneck MD, Poursaid A, Firpo MA, Langell JT. Violet 405\u2009nm light: a novel therapeutic agent against \u03b2-lactam-resistant Escherichia coli. Lasers Surg Med. 2016, 48:311-7. 10.1002\/lsm.22457","journal-title":"Lasers Surg Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2016.08.006","article-title":"Violet 405-nm light: a novel therapeutic agent against common pathogenic bacteria","volume":"206","author":"Barneck MD","year":"2016","unstructured":"Barneck MD, Rhodes NLR, de la Presa M, et al.. Violet 405-nm light: a novel therapeutic agent against common pathogenic bacteria. J Surg Res. 2016, 206:316-24. 10.1016\/j.jss.2016.08.006","journal-title":"J Surg Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2017-0051","article-title":"Antimicrobial efficacy of irradiation with visible light on oral bacteria in vitro: a systematic review","volume":"9","author":"Pummer A","year":"2017","unstructured":"Pummer A, Kn\u00fcttel H, Hiller KA, Buchalla W, Cieplik F, Maisch T. Antimicrobial efficacy of irradiation with visible light on oral bacteria in vitro: a systematic review. Future Med Chem. 2017, 9:1557-74. 10.4155\/fmc-2017-0051","journal-title":"Future Med Chem"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2018.12.002","article-title":"Influence of a visible-light continuous environmental disinfection system on microbial contamination and surgical site infections in an orthopedic operating room","volume":"47","author":"Murrell LJ","year":"2019","unstructured":"Murrell LJ, Hamilton EK, Johnson HB, Spencer M. Influence of a visible-light continuous environmental disinfection system on microbial contamination and surgical site infections in an orthopedic operating room. Am J Infect Control. 2019, 47:804-10. 10.1016\/j.ajic.2018.12.002","journal-title":"Am J Infect Control"},{"key":"ref37","unstructured":"Light-based therapy weakens antibiotic-resistant bacteria. (2022). Accessed. October 6, 2022: https:\/\/today.tamu.edu\/2022\/10\/06\/light-based-therapy-weakens-antibiotic-resistant-bacteria\/."},{"key":"ref38","unstructured":"Researchers at Texas A&M University and the University of S\u00e3o Paulo are using photodynamic therapy to break the dangerous cycle of fighting increasingly resistant bacteria with increasingly stronger antibiotics. (2022). Accessed. October 6, 2022: https:\/\/vpr.tamu.edu\/wp-content\/uploads\/2021\/12\/TAMU-SPRINT-2021.pdf."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0470-1","article-title":"The potential of visible blue light (405\u2009nm) as a novel decontamination strategy for carbapenemase-producing enterobacteriaceae (CPE)","volume":"8","author":"Halstead FD","year":"2019","unstructured":"Halstead FD, Ahmed Z, Bishop JR, Oppenheim BA. The potential of visible blue light (405\u2009nm) as a novel decontamination strategy for carbapenemase-producing enterobacteriaceae (CPE). Antimicrob Resist Infect Control. 2019, 8:14. 10.1186\/s13756-019-0470-1","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-019-02751-2","article-title":"Effectiveness of 405-nm blue LED light for degradation of Candida biofilms formed on PMMA denture base resin","volume":"34","author":"Tsutsumi-Arai C","year":"2019","unstructured":"Tsutsumi-Arai C, Arai Y, Terada-Ito C, et al.. Effectiveness of 405-nm blue LED light for degradation of Candida biofilms formed on PMMA denture base resin. Lasers Med Sci. 2019, 34:1457-64. 10.1007\/s10103-019-02751-2","journal-title":"Lasers Med Sci"},{"key":"ref41","article-title":"Efficacy of antimicrobial 405 nm blue-light for inactivation of airborne bacteria","volume":"10479","author":"Dougall L","year":"2018","unstructured":"Dougall L, Anderson JG, Timoshkin I, et al.. Efficacy of antimicrobial 405 nm blue-light for inactivation of airborne bacteria. Proc. SPIE (Society of Photographic Instrumentation Engineers). 2018, 10479 :104791G-11.","journal-title":"Proc. SPIE (Society of Photographic Instrumentation Engineers)"},{"key":"ref42","unstructured":"Infection control today - visible-light continuous environmental disinfection system reduces pathogens. (2023). Accessed. August 3, 2023: https:\/\/www.infectioncontroltoday.com\/view\/visible-light-continuous-environmental-disinfection-system-reduces-pathogens."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2013.37035","article-title":"Optical radiation in modern medicine","volume":"30","author":"Sowa P","year":"2013","unstructured":"Sowa P, Rutkowska-Talipska J, Rutkowski K, Koszty\u0142a-Hojna B, Rutkowski R. Optical radiation in modern medicine. Postepy Dermatol Alergol. 2013, 30:246-51. 10.5114\/pdia.2013.37035","journal-title":"Postepy Dermatol Alergol"},{"key":"ref44","unstructured":"Cleveland Clinic phototherapy (light therapy). (2023). Accessed. July 1, 2023: https:\/\/my.clevelandclinic.org\/health\/treatments\/24385-phototherapy-light-therapy."},{"key":"ref45","unstructured":"FDA-cleared light therapy devices LED Technologies Inc. (2023). Accessed. July 1, 2023: https:\/\/ledtechnologies.com\/blog\/fda-cleared-light-therapy-devices\/."},{"key":"ref46","unstructured":"Reveallux - conditions treated\r\n. (2023). Accessed. July 1, 2023: https:\/\/revealluxmedical.com\/conditions-treated\/."},{"key":"ref47","unstructured":"Kenall - safe, continuous, game-changing. visible light disinfection. (2023). Accessed: July 1, 2023: https:\/\/kenall.com\/Indigo-Clean."},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.5664\/jcsm.27445","article-title":"Illuminating rationale and uses for light therapy","volume":"5","author":"Shirani A","year":"2009","unstructured":"Shirani A, St. Louis EK. Illuminating rationale and uses for light therapy. J Clin Sleep Med. 2009, 5:155-63.","journal-title":"J Clin Sleep Med"},{"key":"ref49","unstructured":"News medical and life sciences - what is light therapy?. (2023). Accessed. July 1, 2023: https:\/\/www.news-medical.net\/health\/What-is-Light-Therapy.aspx."},{"key":"ref50","unstructured":"Combating antimicrobial resistance, a global threat. (2018). Accessed. June 15, 2021: https:\/\/www.cdc.gov\/drugresistance\/index.html."},{"key":"ref51","article-title":"Antibiotic Resistant Threats in the United States","author":"US Department of Health and Human Services Centers for Disease Control","year":"2013","unstructured":"US Department of Health and Human Services Centers for Disease Control. Antibiotic Resistant Threats in the United States. CDC, Washington, DC; 2013."},{"key":"ref52","unstructured":"Light Line Medical. (2014). Accessed. June 19, 2014: http:\/\/www.lightlinemedical.com\/about."},{"key":"ref53","unstructured":"Products. (2020). Accessed. January 20, 2020: http:\/\/www.lightlinemedical.com\/products18."},{"key":"ref54","article-title":"The Safety and Efficacy of Visible Light Phototherapy on Reducing Ventilator Associated Infections in Ovine","author":"Rhodes N","unstructured":"Rhodes N, Allen J, Dahl MJ, Langell J, Albertine K. The Safety and Efficacy of Visible Light Phototherapy on Reducing Ventilator Associated Infections in Ovine. University of Utah School of Medicine, Utah;"},{"key":"ref55","unstructured":"Technical Report. Keiretsu internal due diligence study. (2021). Accessed: June 1, 2021: https:\/\/www.keiretsuforum.com\/due-diligence."},{"key":"ref56","unstructured":"Light Line Medical Internal Microbiology Report (confidential subject to NDA). (2023). Accessed. March 5, 2023: https:\/\/lightlinemedical.com\/wp-content\/uploads\/2023\/05\/Poster_1123_Annual_Dialysis_Conference_2023_Poster-Lightingth...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/133989-hospital-catheter-peritoneal-dialysis-acquired-infections-visible-light-as-a-new-solution-to-reduce-risk-and-incidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:06Z","timestamp":1707508866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/133989-hospital-catheter-peritoneal-dialysis-acquired-infections-visible-light-as-a-new-solution-to-reduce-risk-and-incidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,6]]},"references-count":56,"URL":"https:\/\/doi.org\/10.7759\/cureus.43043","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,6]]}}}